Kurma Partners closes €215 million Biofund IV to back European BioTech ventures from Paris
Source ↗
👁 0
💬 0
Kurma Partners, a French healthcare venture capital firm, announced the final closing of Biofund IV at €215 million to support the discovery and development of disruptive therapeutic solutions for severe or incurable diseases.
Building on the €160 million Biofund III, this fundraise has increased the new vehicle’s size by nearly 35%. Biofund IV is backed by three cornerstone investors – the Australian pharmaceutical company CSL, the European Investment Fund (EIF), and Bpifrance (whic
Building on the €160 million Biofund III, this fundraise has increased the new vehicle’s size by nearly 35%. Biofund IV is backed by three cornerstone investors – the Australian pharmaceutical company CSL, the European Investment Fund (EIF), and Bpifrance (whic
Comments (0)